Find AMR Resources
Connecting the AMR community with the solutions it needs
The tools advancing the AMR response are as diverse as the problem itself, spanning contract services, diagnostics, surveillance platforms, infection prevention technologies, digital technologies, and beyond. This growing directory brings them together in one place, making it easier for researchers, clinicians, investors, and advocates to find, evaluate, and connect with the solutions the global AMR fight needs.
LeAF is an independent research and consulting organization based at Wageningen University\'s Environmental Technology department. It specializes in recovering and safely reusing water, energy, and nutrients from solid and liquid waste streams, with particular expertise in pharmaceutical residues, PFAS, and other micropollutants , including antibiotic removal technologies relevant to AMR risk reduction in wastewater.
LightOx is a Durham-based company developing light-activated therapeutic agents with applications in photodynamic antimicrobial therapy and cancer treatment. Its molecular tools use light activation to generate localized antimicrobial activity , targeting bacterial biofilms and resistant organisms in wound and oral infection settings without systemic antibiotic exposure, offering a resistance-independent therapeutic approach for localized drug-resistant infections.
Liofilchem is an Italian manufacturer of microbiological culture media, antimicrobial susceptibility testing products, and in vitro diagnostics for clinical microbiology laboratories. Its product line includes MIC Test Strips, chromogenic media, and AST panels used worldwide for resistance testing and breakpoint determination. Liofilchem\'s products are essential tools in clinical laboratories\' frontline efforts to identify drug-resistant infections and guide appropriate antibiotic therapy.
The SAM-UVC disinfection robot is uniquely cost-effective, mobile, and transportable. By applying smart algorithms and AI the robot can also provide accurate digital audit trails for each disinfection task.
Cost-effectiveness studies for non-antibiotic prevention and treatment strategies, including complementary and alternative medicine, for common infections. Implementation and evaluation studies on antimicrobial stewardship.
Lumos Diagnostics is a Carlsbad, California–based point-of-care diagnostics company developing rapid lateral flow tests for infectious diseases and biomarker detection. Its FebriDx platform distinguishes bacterial from viral infection in febrile patients , directly supporting antibiotic stewardship by enabling clinicians to determine when antibiotics are and are not needed, reducing unnecessary antibiotic prescribing in primary care and emergency settings globally.
Mast Group is a UK-based manufacturer of antimicrobial susceptibility testing products, supplying clinical microbiology laboratories globally with disc diffusion tests, MIC gradient strips, culture media, and quality control materials. Its products are used daily in hospital laboratories to determine antibiotic resistance profiles of clinical isolates , providing the frontline testing infrastructure that clinicians depend on to prescribe effective antibiotics for drug-resistant infections.
In order to limit the emergence of antibiotic resistance bacteria, effective and cost effective solutions are required to guide the appropriate use of antibiotics. Mast Group Ltd. supports tackling the AMR challenge and accordingly for many years has continually updated its portfolio of products. Products incorporate a variety of applications to enable screening for the presence or absence of resistant bacteria and confirmatory tests for implementation of infection control measures to limit the spread of resistant pathogens.
Matoke Holdings is a UK-based medtech company developing Reactive Oxygen (RO) technology for chronic wound care and infection management. Its platform generates reactive oxygen species to combat drug-resistant biofilm infections in wounds without conventional antibiotics , offering a clinically validated, resistance-independent approach to treating chronic infections caused by MRSA, Pseudomonas, and other multidrug-resistant organisms in wound care settings.
MetalloBio is a UK-based biotechnology company developing novel metal-based antimicrobial compounds to combat drug-resistant infections. Its platform exploits the antibacterial properties of metal ions to create agents effective against multidrug-resistant pathogens that have defeated conventional antibiotics. The company is currently crowdfunding through Republic Europe as it advances its pipeline of AMR-targeted antimicrobial solutions toward clinical development.
Microbira is an Edinburgh-based company developing non-antibiotic antimicrobial technologies for infection prevention and treatment. Its platform focuses on novel compounds and delivery systems that kill or inhibit drug-resistant bacteria through mechanisms that do not select for resistance , providing alternatives to conventional antibiotics for surface disinfection, wound care, and infection prevention in healthcare environments with high rates of resistant organism transmission.
Microplate Dx is a Leeds-based diagnostics company developing rapid, affordable antimicrobial susceptibility testing solutions designed to work in low-resource clinical settings. Its microplate-based platform aims to make actionable resistance testing accessible in the healthcare systems where diagnostic capacity is weakest , precisely the settings where AMR burden is highest and inappropriate antibiotic prescribing is most consequential.
MicuRx Pharmaceuticals is a global biopharmaceutical company headquartered in Shanghai with operations in California. It develops novel antibiotics targeting drug-resistant bacterial infections, with its lead product contezolid approved in China for MRSA and complicated skin infections. The company is advancing MRX-5 into Phase 2 trials for Mycobacterium abscessus pulmonary disease , a notoriously difficult-to-treat nontuberculous mycobacterial infection.
N8 Medical is a Richmond, Virginia–based medical device company developing novel photodynamic inactivation devices for decolonization of drug-resistant pathogens. Its NovaBay platform uses light-activated antimicrobial compounds to eliminate MRSA and other resistant organisms from nasal passages before surgery , reducing healthcare-associated infection risk without antibiotics, supporting infection prevention programs in hospital settings with high resistant pathogen carriage rates.
NewGenne is a Cambridge-based biotechnology company developing novel antibiotics using synthetic biology and metabolic engineering to produce next-generation natural product-derived antimicrobials. Its platform applies advanced gene-cluster mining and pathway engineering to discover and optimize bacterial natural products with activity against drug-resistant pathogens, targeting compound classes with new mechanisms of action not represented in the current antibiotic pipeline.
NG Biotech is a French manufacturer of rapid lateral flow diagnostic tests, including point-of-care assays for antimicrobial resistance detection in both human and veterinary settings. Its AMR-specific test portfolio helps clinicians and veterinarians rapidly identify resistant infections at the bedside or farm, enabling appropriate antibiotic selection while reducing unnecessary broad-spectrum prescribing across human and animal health settings.
Nijhuis Saur Industries is a global provider of industrial and municipal water treatment systems, offering solutions for filtration, purification, and wastewater management. Its technologies address the removal of pharmaceutical contaminants from water streams , including antibiotic residues that contribute to environmental AMR spread , supporting clean water and compliance goals across healthcare, food, and industrial sectors.
Nostics is a Vienna-based diagnostics company developing rapid point-of-care molecular tests for infectious diseases. Its platform provides fast, accurate pathogen identification to guide clinical decision-making at the time of patient presentation , supporting antimicrobial stewardship by enabling clinicians to prescribe targeted antibiotics rather than broad-spectrum empirical treatments that accelerate resistance development.
NYtor designs and develops molecular detection assays in the field of human and veterinary infectious disease diagnostics. Our main focus is the development of smart molecular assays for the detection of antibiotic resistance.
Stay connected so that you don't miss the latest AMR insights and updates.
